Overview

Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer

Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to determine the activity of sorafenib in patients with advanced (metastatic or recurrent) thyroid cancer.
Phase:
Phase 2
Details
Lead Sponsor:
University of Pennsylvania
Treatments:
Sorafenib